Summary
The provided AI claims focus on renal toxicity, monitoring, drug interactions, and caregiver symptom cues. However, the supplied Jylamvo label excerpts do not include any renal-toxicity details, monitoring instructions, interaction listings, or specific adverse reaction manifestations beyond listing 'Renal Toxicity' as a category. Therefore, almost all specific safety/monitoring/interaction statements are unsupported by the provided label text and cannot be validated against it.
Category Scores
Accurate Statements
Methotrexate can cause toxicity throughout the body when it accumulates.
Supported only in a very general way by the label's mention of 'Increased Risk of Adverse Reactions Due to Third-Space Accumulation' (6 ADVERSE REACTIONS). Specific wording about 'throughout the body' and accumulation mechanism for renal toxicity is not present in the supplied excerpts.
Methotrexate toxicity includes renal toxicity.
The label adverse reactions section includes 'Renal Toxicity' as a clinically significant adverse reaction category (6 ADVERSE REACTIONS). The supplied excerpt does not provide the specific renal manifestations/monitoring details claimed.
Unsupported Statements
Methotrexate can stress the kidneys mainly by increasing drug levels when kidney function is reduced.
The provided label excerpts do not describe the mechanism 'mainly by increasing drug levels when kidney function is reduced' or renal mechanism details.
Reduced kidney clearance in older adults increases the likelihood of kidney-related toxicity from methotrexate.
The provided label excerpts do not include statements about older adults, kidney clearance, or increased likelihood of renal toxicity in older adults.
Methotrexate toxicity can appear like acute kidney injury.
No text in the supplied label excerpts states this presentation relationship.
Methotrexate can cause rising serum creatinine and worsening kidney function.
No serum creatinine/eGFR or specific renal lab changes are present in the supplied excerpts.
Methotrexate can worsen dehydration-related kidney stress.
No dehydration-specific renal risk language is present in the supplied excerpts.
Methotrexate can cause urine abnormalities when toxicity is more severe.
No urine abnormalities are described in the supplied label excerpts.
Methotrexate can cause reduced urine output when toxicity is more severe.
No reduced urine output guidance is present in the supplied label excerpts.
Methotrexate toxicity is more likely when methotrexate is not cleared well and the body accumulates the drug or its metabolites.
The supplied excerpts only mention 'Increased Risk of Adverse Reactions Due to Third-Space Accumulation' without the specific phrasing about renal clearance/metabolite accumulation.
Older adults often have reduced baseline kidney clearance.
No geriatric baseline kidney clearance statements are present in the supplied label excerpts.
Older adults may take other medications that affect kidney blood flow or kidney excretion.
No statement in the supplied label excerpts discusses this.
Reduced baseline kidney clearance and concomitant medications can raise methotrexate exposure.
No exposure-increase statement tied to kidney clearance and concomitant medications is present in the supplied excerpts.
Higher methotrexate exposure increases the chance of kidney injury and related systemic side effects.
The provided excerpts do not link exposure magnitude to kidney injury/systemic side effects.
Chronic kidney disease or age-related decline in kidney function increases the risk of methotrexate toxicity.
No CKD/age-related risk statements are included in the supplied excerpts.
Dehydration from illness, poor oral intake, or vomiting/diarrhea increases the risk of methotrexate toxicity.
No dehydration/illness-related risk statements are included in the supplied excerpts.
Drug interactions can reduce methotrexate clearance or increase toxicity.
No drug interaction language is provided in the supplied label excerpts.
Certain pain medicines can reduce methotrexate clearance or increase toxicity.
No specific interaction drug class/examples are provided in the supplied label excerpts.
Certain antibiotics or other drugs can reduce methotrexate clearance or increase toxicity.
No specific antibiotic/other drug interaction content is provided in the supplied label excerpts.
Caregivers should watch for less urination than usual as a possible sign of kidney injury from methotrexate.
No caregiver monitoring instructions or 'less urination' symptom cue is in the supplied excerpts.
Caregivers should watch for swelling in legs/feet or sudden weight gain as a possible sign of kidney injury from methotrexate.
No such symptom cue is present in the supplied excerpts.
Kidney injury from methotrexate can present with new or worsening fatigue, weakness, or feeling unwell.
No specific symptom associations are provided in the supplied excerpts.
Lab changes such as higher creatinine or abnormal kidney function tests after starting or increasing the dose can occur with methotrexate kidney injury.
No creatinine/eGFR monitoring or dose-timing lab change statements are included in the supplied excerpts.
If methotrexate toxicity is more severe, older adults may experience symptoms outside the kidneys such as mouth sores.
No age-stratified or severity-dependent symptom expansion beyond categories is provided in the supplied excerpts.
If methotrexate toxicity is more severe, older adults may experience symptoms outside the kidneys such as unusual bruising or bleeding.
No bruising/bleeding symptom cue is provided in the supplied excerpts.
If methotrexate toxicity is more severe, older adults may experience symptoms outside the kidneys such as severe diarrhea.
No severity-dependent diarrhea symptom cue is provided in the supplied excerpts.
Clinicians generally monitor kidney function with serum creatinine and estimated glomerular filtration rate (eGFR) during methotrexate safety monitoring.
The supplied excerpts do not provide any monitoring recommendations for kidney function or mention creatinine/eGFR.
Methotrexate safety monitoring sometimes includes additional labs because methotrexate can affect blood counts and liver function.
The supplied excerpts mention 'Myelosuppression' and 'Hepatotoxicity' only as described elsewhere, but do not state additional labs or monitoring details.
Monitoring kidney function is especially important after starting methotrexate, after dose changes, and during acute illnesses that could cause dehydration.
No such timing-based monitoring guidance is present in the supplied excerpts.
Low blood counts from methotrexate toxicity can present as infections, fever, or unusual bleeding.
No such clinical presentations are included in the supplied excerpts.
Methotrexate gastrointestinal toxicity can include nausea, vomiting, and diarrhea.
The supplied excerpts list 'Gastrointestinal Toxicity' as a category but do not provide specific symptom list.
Gastrointestinal toxicity from methotrexate can worsen dehydration and indirectly stress the kidneys.
No dehydration linkage is provided in the supplied excerpts.
Methotrexate can cause mouth sores or inflammation.
No specific mouth sores/inflammation detail is present in the supplied excerpts.
Urgent medical advice is recommended if an older adult on methotrexate develops markedly decreased urine output.
No urgent/caregiver action guidance or urine output symptom-based instructions are present in the supplied excerpts.
Urgent medical advice is recommended if an older adult on methotrexate develops severe vomiting/diarrhea, inability to drink fluids, or signs of dehydration.
No such urgent advice instructions are present in the supplied excerpts.
Urgent medical advice is recommended if an older adult on methotrexate develops fever or feels significantly worse.
No urgent action instructions or fever/worsening guidance is provided in the supplied excerpts.
Urgent medical advice is recommended if an older adult on methotrexate develops new swelling or rapidly worsening weakness.
No such urgent action symptom-based instructions are present in the supplied excerpts.
Clinicians often recommend checking kidney function immediately and reviewing interacting medications if kidney injury is suspected in patients taking methotrexate.
No monitoring/interaction action steps are provided in the supplied excerpts.
Certain drug combinations can increase methotrexate toxicity risk in older adults by affecting kidney function or methotrexate clearance.
No drug combination guidance or older-adult-specific interaction risk language is provided in the supplied excerpts.
Certain pain-reliever/anti-inflammatory medicines can increase methotrexate toxicity risk in older adults by affecting kidney function or methotrexate clearance.
No specific NSAID/pain-reliever interaction content is provided in the supplied excerpts.
Certain antibiotics and other drugs can increase methotrexate toxicity risk in older adults by affecting kidney function or methotrexate clearance.
No specific antibiotic interaction content is provided in the supplied excerpts.
Methotrexate gastrointestinal toxicity can include nausea, vomiting, and diarrhea.
Duplicate unsupported statement; symptom specifics not present in the supplied excerpts.
Contradictions
Important Omissions
Key contraindication and pregnancy-reproductive counseling content relevant to the label (e.g., JYLAMVO contraindicated in pregnant women for non-neoplastic diseases; hypersensitivity/anaphylaxis contraindication; contraception timing).
Importance:
High
Medication error and dosing-regimen safety instructions (e.g., deaths due to dosing errors; weekly vs daily regimen; instruct patients/caregivers accordingly).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Many claims provide detailed renal toxicity mechanisms, symptom cues, and monitoring/interaction guidance that are not supported by the supplied JYLAMVO label excerpts. This increases the chance of non-label-conformant clinical instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims about renal toxicity presentation, caregiver monitoring for specific symptoms (urine output, swelling/weight gain), and drug interaction classes/monitoring are not present in the provided Jylamvo label excerpts.
Suggested Improvement
Restrict statements to label-supported content from the provided excerpts (e.g., mention that 'Renal Toxicity' is a described adverse reaction category) and include label-supported contraindications/warnings (pregnancy contraindication for non-neoplastic disease, severe hypersensitivity including anaphylaxis, and medication error/dosing regimen instructions) when discussing safety-critical information.